Vanguard Group Inc Spectrum Pharmaceuticals Inc Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.65 - $1.31 $128,253 - $258,480	-197,313 Reduced 2.25%	8,580,357 $8.24 Million
Q1 2023 May 15, 2023	BUY	$0.38 - $1.07 $143,405 - $403,799	377,383 Added 4.49%	8,777,670 $6.58 Million
Q4 2022 Feb 10, 2023	SELL	$0.32 - $0.52 $85,386 - $138,753	-266,833 Reduced 3.08%	8,400,287 $3.11 Million
Q3 2022 Nov 14, 2022	SELL	$0.43 - $1.56 $69,469 - $252,027	-161,556 Reduced 1.83%	8,667,120 $3.73 Million
Q2 2022 Aug 12, 2022	BUY	$0.7 - $1.4 $605,425 - $1.21 Million	864,894 Added 10.86%	8,828,676 $6.89 Million
Q1 2022 May 13, 2022	SELL	$0.63 - $1.59 $962,979 - $2.43 Million	-1,528,539 Reduced 16.1%	7,963,782 $10.3 Million
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.42 $1.56 Million - $2.97 Million	-1,228,856 Reduced 11.46%	9,492,321 $12.1 Million
Q3 2021 Nov 12, 2021	SELL	$2.15 - $3.82 $5.64 Million - $10 Million	-2,623,108 Reduced 19.66%	10,721,177 $23.4 Million
Q2 2021 Aug 13, 2021	BUY	$2.89 - $4.45 $38.6 Million - $59.4 Million	13,344,285 New	13,344,285 $50 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.